Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

Partner | Cancer Centers | <b>RWJBarnabas Health and Rutgers Cancer Institute of New Jersey</b>

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Saum Ghodoussipour, MD, urologic oncologist, director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute of New Jersey, assistant professor of surgery, Rutgers Robert Wood Johnson (RWJ) Medical School, RWJ University Hospital, discusses ongoing trials in renal cell carcinoma (RCC) and prostate cancer.

Although patients with metastatic RCC and prostate cancer are typically managed with systemic therapies, several ongoing clinical trials are evaluating the role of cytoreductive surgery in this setting, Ghodoussipour says. Early evidence suggests that cytoreductive surgery may have utility in the metastatic setting for these patient populations, Ghodoussipour explains.

Regarding RCC, the phase 2 Cyto-KIK trial (NCT04322955) is evaluating the utility of neoadjuvant and adjuvant nivolumab (Opdivo) plus cabozantinib (Cabometyx) with cytoreductive surgery in patients with metastatic RCC, Ghodoussipour says. In prostate cancer, the phase 2 SIMCAP study (NCT03456843) is examining the role of radical prostatectomy plus antiandrogen agents with or without docetaxel in men with newly diagnosed metastatic prostate cancer. The results of the study may inform whether it is possible to prolong survival and delay progression of disease with surgery and best systemic therapy, Ghodoussipour concludes.